Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

NMUS / Nemus Bioscience, Inc. FROM 8-K (Current Report)

2018-02-20 sec.gov
nmus_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 16, 2018 (February 16, 2018)   Nemus Bioscience, Inc. (Exact name of registrant as specified in its charter)   Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No. (2-0)

NMUS / Nemus Bioscience, Inc. FORM 8-K (Current Report)

2018-02-13 sec.gov
nmus_8k.htm     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 13, 2018   Nemus Bioscience, Inc. (Exact name of registrant as specified in its charter)   Nevada   000-55136   45-0692882 (State or Other Jurisdiction   (Commission File   (I.

NMUS / Nemus Bioscience, Inc. 424B3 (Prospectus)

2018-02-13 sec.gov
nemus_424b3.htm     Filed pursuant to Rule 424(b)(3) Registration Nos. 333-221733 333-216664 333-206992 333-214761 333-215645   PROSPECTUS SUPPLEMENT NO. 3 (To Prospectus Dated December 4, 2017)   NEMUS BIOSCIENCE, INC.   Up to 50,159,997 Shares of Common Stock   This prospectus supplement no. 3 supplements the prospectus dated December 4, 2017 relating to the resale by the selling shareholders identified in the prospectus of up to 50,159,997 shares of our common stock, $0.

NMUS / Nemus Bioscience, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-30 fintel.io
Nemus Bioscience, Inc. (OTC:NMUS) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 76,735,000 shares. Largest shareholders include Emerald Health Sciences Inc.. (2-0)

NMUS / Nemus Bioscience, Inc. / Emerald Health Sciences Inc. - SC 13D (Activist Investment)

2018-01-30 sec.gov
nemus_sc13d.htm   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D Under the Securities Exchange Act of 1934*   Nemus Bioscience, Inc. (Name of Issuer)   Common Stock, $.001 par value (Title of Class of Securities)   64046J100 (CUSIP Number)   Emerald Health Sciences Inc. Office 8262, The Landing, 200 – 375 Water St. Vancouver, British Columbia, Canada V6B 0M9 858-361-4499   (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications)  

NMUS / Nemus Bioscience, Inc. / Emerald Health Sciences Inc. - SC 13D (Activist Investment)

2018-01-30 sec.gov
nemus_sc13d.htm   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13D Under the Securities Exchange Act of 1934*   Nemus Bioscience, Inc. (Name of Issuer)   Common Stock, $.001 par value (Title of Class of Securities)   64046J100 (CUSIP Number)   Emerald Health Sciences Inc. Office 8262, The Landing, 200 – 375 Water St. Vancouver, British Columbia, Canada V6B 0M9 858-361-4499   (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications)  

NMUS / Nemus Bioscience, Inc. FORM 424B3 (Prospectus)

2018-01-23 sec.gov
nemus_424b3.htm   Filed pursuant to Rule 424(b)(3) Registration Nos. 333-221733 333-216664 333-206992 333-214761 333-215645     PROSPECTUS SUPPLEMENT NO. 2 (To Prospectus Dated December 4, 2017)     NEMUS BIOSCIENCE, INC.   Up to 50,159,997 Shares of Common Stock   This prospectus supplement no. 2 supplements the prospectus dated December 4, 2017 relating to the resale by the selling shareholders identified in the prospectus of up to 50,159,997 shares of our common stock, $0.

NMUS / Nemus Bioscience, Inc. FORM 8-K (Current Report)

2018-01-22 sec.gov
nemus_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 22, 2018 (January 18, 2018)   Nemus Bioscience, Inc. (Exact name of registrant as specified in its charter)   Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

NMUS / Nemus Bioscience, Inc. ER

2018-01-04 sec.gov
November 30, 2017 Brian Murphy Chief Executive Officer Nemus Bioscience, Inc. 600 Anton Blvd., Suite 1100 Costa Mesa, CA 92626 Nemus Bioscience, Inc. Registration Statement on Form S-1 Filed November 22, 2017 File No. 333-221733 Re: Dear Dr. Murphy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration.

NMUS / Nemus Bioscience, Inc. ESP

2018-01-04 sec.gov
nemus_corresp.htm Nemus Bioscience, Inc. 600 Anton Blvd., Suite 1100 Costa Mesa, CA 92626 (949) 396-0330   December 1, 2017   VIA EDGAR   Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549   Attention: Ms. Ada D. Sarmento   Re: Nemus Bioscience, Inc. Registration Statement on Form S-1 File No. 333-221733   Dear Ms. Sarmento:   Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nemus Bioscience, In

NMUS / Nemus Bioscience, Inc. FORM 8-K (Current Report)

2018-01-03 sec.gov
nemus_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): January 3, 2018 (December 28, 2017)   Nemus Bioscience, Inc. (Exact name of registrant as specified in its charter)   Nevada 000-55136 45-0692882 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

NMUS / Nemus Bioscience, Inc. FORM 424B3 (Prospectus)

2018-01-03 sec.gov
nemus_424b3.htm   Filed pursuant to Rule 424(b)(3) Registration Nos. 333-221733 333-216664 333-206992 333-214761 333-215645     PROSPECTUS SUPPLEMENT NO. 1 (To Prospectus Dated December 4, 2017)     NEMUS BIOSCIENCE, INC.   Up to 50,159,997 Shares of Common Stock   This prospectus supplement no. 1 supplements the prospectus dated December 4, 2017 relating to the resale by the selling shareholders identified in the prospectus of up to 50,159,997 shares of our common stock, $0.

NMUS / Nemus Bioscience, Inc. 424B3 (Prospectus)

2017-12-05 sec.gov
nemus_424b3.htm Filed pursuant to Rule 424(b)(3) Registration Nos. 333-221733 333-216664 333-206992 333-214761 333-215645     Prospectus     NEMUS BIOSCIENCE, INC.   Up to 50,159,997 Shares of Common Stock   This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to 50,159,997 shares of our common stock, $0.001 par value, including (i) 20,000,000 shares of common stock, which equals the number of shares of common stock issuable upon the conversion of

NMUS / Nemus Bioscience, Inc. FORM S-1

2017-11-22 sec.gov
nemus_s1.htm As filed with the Securities and Exchange Commission on November 22, 2017 Registration No. 333-___________      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________   FORM S-1   REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 ___________________   NEMUS BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) ___________________   Nevada   2834   45-0692882 (State or other jurisdiction of incorporation or organization)  

NMUS / Nemus Bioscience, Inc. FORM 10-Q (Quarterly Report)

2017-11-15 sec.gov
nemus_10q.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 10-Q   (Mark One)   x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       For the quarterly period ended September 30, 2017   or   o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934       For the transition period from ___________ to ___________      Commission File Number: 000-55136   Nemus Bioscience, Inc.


NMUS : Nemus Bioscience Analysis and Research Report

Nemus Bioscience is a biopharmaceutical company focused on the discovery, development, and the commercialization of cannabis-based therapeutics, or cannabinoids, through its partnership with the University of Mississippi, or UM. UM has held the only contract to cultivate cannabis for research purposes on behalf of the Federal Government since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, process and manufacture of cannabis extracts. Nemus Bioscience is currently UM's sole partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids, and the realization of this partnership will depend on the successful navigation of the complex regulatory framework for the cultivation and handling of cannabis in the United States.

Recent Events and Significant Contracts

UM 5050 pro-drug agreements:

On September 29, 2014, the Company executed three license agreements with UM pursuant to whi...

Click for full article
CUSIP: 64046J100